| 000 | 03202naaaa2200721uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/69310 | ||
| 005 | 20220220044255.0 | ||
| 020 | _abooks978-3-03943-502-9 | ||
| 020 | _a9783039435012 | ||
| 020 | _a9783039435029 | ||
| 024 | 7 |
_a10.3390/books978-3-03943-502-9 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 072 | 7 |
_aGP _2bicssc |
|
| 072 | 7 |
_aPS _2bicssc |
|
| 100 | 1 |
_aVenketaraman, Vishwanath _4edt |
|
| 700 | 1 |
_aVenketaraman, Vishwanath _4oth |
|
| 245 | 1 | 0 | _aHost-Directed Therapies for Tuberculosis |
| 260 |
_aBasel, Switzerland _bMDPI - Multidisciplinary Digital Publishing Institute _c2020 |
||
| 300 | _a1 electronic resource (120 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aTB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entire world's population has latent TB. Consequently, there has been a worldwide effort to eradicate and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb. Furthermore, when administered, many of the anti-TB drugs commonly present severe complications and side effects. Novel approaches to enhance the host immune responses to completely eradicate Mtb infection are urgently needed. This Special Issue will therefore cover most recent advances in the area of host-directed therapies for TB. | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by/4.0/ _2cc _4https://creativecommons.org/licenses/by/4.0/ |
||
| 546 | _aEnglish | ||
| 650 | 7 |
_aResearch & information: general _2bicssc |
|
| 650 | 7 |
_aBiology, life sciences _2bicssc |
|
| 653 | _aMycobacterium tuberculosis | ||
| 653 | _ahost-directed therapies | ||
| 653 | _aimmune responses | ||
| 653 | _atuberculosis | ||
| 653 | _alung cancer | ||
| 653 | _amisdiagnosis | ||
| 653 | _ainvasive procedure | ||
| 653 | _arevising | ||
| 653 | _aantiplatelet | ||
| 653 | _aaspirin | ||
| 653 | _aimmunomodulation | ||
| 653 | _asurvival | ||
| 653 | _aTaiwan | ||
| 653 | _alatent infection | ||
| 653 | _apulmonary | ||
| 653 | _arabbit | ||
| 653 | _airon supplementation | ||
| 653 | _apathology | ||
| 653 | _aimmune response | ||
| 653 | _agene expression | ||
| 653 | _aPerls’ stain | ||
| 653 | _aautophagy | ||
| 653 | _aM. tb | ||
| 653 | _aBCG vaccination | ||
| 653 | _aimmune exhaustion | ||
| 653 | _aglutathione | ||
| 653 | _acytokines | ||
| 653 | _agranulomas | ||
| 653 | _atype 2 diabetes | ||
| 653 | _aco-morbidities | ||
| 653 | _aco-infections | ||
| 653 | _ainflammation | ||
| 653 | _aredox imbalance | ||
| 653 | _aantioxidants | ||
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://mdpi.com/books/pdfview/book/3102 _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/69310 _70 _zDOAB: description of the publication |
| 999 |
_c65766 _d65766 |
||